Use of an agent consisting of antibodies and/or insulin-like growth factor antagonists
The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
1. A method for treating oral mucositis after radiotherapy and/or chemotherapy comprising the step of administering orally to a subject in need thereof, a pharmaceutical preparation comprising an efficacious amount of IgY antibodies or their fragments, wherein said IgY antibodies or their fragments are anti-lipopolysaccharide polyclonal antibodies obtained from egg yolk of hens immunized with Gram-negative bacteria.
2. The method according to claim 1 , wherein the preparation comprises anti-lipopolysaccharide IgY antibodies obtained from egg yolk of immunized chickens.
3. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 0.1-10.0 g.
4. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 1.0-8.0 g.
5. The method according to claim 1 , wherein the treatment is carried out by administering a daily dose of a formulation prepared for administration of 2.0-7.0 g.
6. The method according to claim 1 , wherein the treatment is carried out by a daily administration for 4-14 weeks.
7. The method according to claim 1 , characterized in that the oral mucositis after radiotherapy and/or chemotherapy is present in a patient further suffering from an idiopathic pain syndrome.
8. The method according to claim 1 , wherein the oral mucositis after radiotherapy and/or chemotherapy is present in a patient with a defective biological barrier against bacterial endotoxin.
9. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 1.5 wt % based on the total weight of the preparation.
10. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 2.0 wt % based on the total weight of the preparation.
11. The method according to claim 1 , wherein said IgY antibodies or their fragments represent at least 5.0 wt % based on the total weight of the preparation.
12. The method according to claim 1 , wherein said IgY antibodies or their fragments represent 100% of the total antibody content of the preparation.